


IN THE CLAIMS

The status of each claim of the present application is listed below.

Claims 1-41: Canceled.

42. (New) A compound represented by the formula:



or a pharmaceutically acceptable salt thereof.

43. (New) The compound of Claim 42, which is *cis*-substituted.

44. (New) The compound of Claim 42, which is *trans*-substituted.

45. (New) A method of binding opioid receptors, comprising administering an effective amount of the compound of Claim 42 or a pharmaceutically acceptable salt thereof to a mammalian subject in need thereof.

46. (New) The method of Claim 45, wherein delta opioid receptors are bound.

48. (New) The method of Claim 45, wherein the compound functions as an agonist selective for the delta receptor.

SUPPORT FOR THE AMENDMENT

Newly-added Claims 42-48 are supported by the specification at pages 11-137 and the original claims. See in particular Example beginning at page 122 and Figure 17. Compounds 3a and 3b are specified in newly-added Claim 42. No new matter is believed to have been added by entry of this amendment. Entry and favorable reconsideration are respectfully requested.